Heikki Lanckriet, Pilar de la Huerta, Peter Llewellyn-Davis
Sygnis has announced changes to its management team and supervisory board. Former Co-CEO Heikki Lanckriet will become sole CEO of the company and will also retain his role as CSO. Additionally, supervisory board members Maria-Hesús Sabatés Mas and Franz Wilhelm Hopp will be ending their appointment terms and will not be up for re-election. Pilar de la Huerta and Peter Llewellyn-Davis will be nominated to replace them. De la Huerta will also resign from her position as member of the management board. Llewellyn-Davis currently serves as non-executive director and chairman of the audit committee of Shield Therapeutics. He previously served as CFO and chief business officer of MediGene.
Joris Veltman has taken the position of director of the Institute of Genetic Medicine at Newcastle University in the UK. He previously served as a professor of translational genomics in the department of human genetics at Radboud University Medical Centre in Nijmegen in the Netherlands, with a joint appointment in the department of clinical genetics at Maastricht University Medical Centre.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.